Prime supports initiative to end the HIV epidemic by 2030
Promotes patient access to preventive care from any pharmacy at no cost
August 5, 2021
Awareness and prevention prior to exposure are integral in reducing the number of people affected by HIV. In part to support this initiative, the United States Preventive Services Task Force (USPSTF) released an Affordable Care Act (ACA) guideline recommending pre-exposure prophylaxis (PrEP) at no cost to anyone at risk of HIV acquisition.³
To align with this initiative, in July 2020, Prime and its Blue Plan clients introduced ACA HIV PrEP benefits that increased access to PrEP antiretroviral medicines for at-risk people. The updated benefit design leveraged claims data to give doctors and their non-HIV infected patients $0 access to PrEP medications while minimizing disruption in therapy and promoting adherence for members already taking the same medicines for HIV post-exposure prophylaxis or treatment in accordance with their benefits.
Prime also has a number of pharmacy network initiatives, including specific HIV and quality of care networks and maintains contracts with many HIV pharmacies to ensure patient access and support their care needs. Patients are able to use any HIV focused pharmacy or other pharmacies of their choice as part of their benefit.
Prime and its Blue Plan clients are committed to helping in the goal to reduce the incidence of HIV infection.
Overview of Market and Prime Therapeutics’ HIV Spending
*blended PrEP + PEP (Post-Exposure Prophylaxis) + treatment & $0 member spend from ACA or client programs
October 15, 2021
MILI and Prime Therapeutics leadership led a virtual panel discussion on Oct. 13,…
October 14, 2021
Frank Aba-Onu, legal counsel at Prime Therapeutics, was part of a team recognized…
September 15, 2021
The Pharmacy Benefit Management Institute (PBMI) honored Prime Therapeutics’ High-Value Pharmacist Managed Care…